May 13, 2025
RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win
May 02, 2025
RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress
Apr 28, 2025
RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107
Apr 16, 2025
RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption
Apr 10, 2025
RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights
Mar 18, 2025
RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation
Mar 12, 2025
RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results
Feb 27, 2025
RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum
Feb 04, 2025
RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer
Jan 21, 2025
RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published
Dec 10, 2024
Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development
Dec 02, 2024
RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court
Oct 28, 2024
RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND
Oct 22, 2024
RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury
Oct 14, 2024
RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment
Oct 01, 2024
RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians
Sep 05, 2024
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Sep 03, 2024
New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality
Aug 29, 2024
RedHill Biopharma Announces First Half 2024 Business Highlights
Aug 26, 2024
RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma